Midwest Association for Toxicology and Therapeutic Drug Monitoring

Final Program

Crowne Plaza Milwaukee-Wauwatosa
10499 Innovation Drive, Wauwatosa, WI 53226
414-475-9500

Wednesday April 28, 2010

5:00-6:30 P.M.	Vendor check-in/setup	Grande Salon
6:30-8:00 P.M.	Dinner/Board Meeting (Executive Committee Only)	King Executive Board

Thursday April 29, 2010

7:00-8:30 A.M.	Registration/Breakfast	Ballroom CDE
8:30-8:45 A.M.	Welcome/Introduction Paul Jannetto, PhD (Meeting Host) Karen Leonard (MATT President)	Ballroom AB
	Pain Management Moderator: GregWallace	Ballroom AB
8:45-9:30 A.M.	**Using TDM and Pharmacogenomics for Pain Management** Nancy Bratanow, MD Director, Midwest Comprehensive Pain Care	

Learning Objectives: After completing this activity, the learner will be able to:

1. Describe the limitations of testing for opioid compliance in pain management patients.
2. Explain the use of TDM and Pharmacogenomics to understand clinical efficacy and toxicity in pain patients.
3. Discuss clinical case studies where Pharmacogenomics and TDM may have improved the individualization of pain management therapy

9:30-10:15 A.M. **Pharmacologic Treatment of Opiate Addiction**
Lance P. Longo, MD
Medical Director, Addition Psychiatry
Aurora Behavioral Health Services

Learning Objectives: After completing this activity, the learner will be able to:

1. Explain the use of available pharmacotherapy's (i.e. methadone) for treating opiate addiction.
2. Compare and contrast the advantages and disadvantages of using buprenorphine vs. methadone for opiate dependence.
3. Recognize the signs and symptoms of opiate withdrawal

10:15-10:30 A.M. Break

Drug of Abuse and Alcohol Testing

Ballroom AB

Moderator: GregWallace

10:30-11:00 A.M. **Nothing Can Seem Foul to Those that Win: Deception in Urine Drug Testing**
Norma Erickson, BA, CLT(HEW)

Learning Objectives: After completing this activity, the learner will be able to:

1. List tested populations and their typical collection procedures.
2. Identify six methods of in vitro adulteration.
3. Describe in vivo adulteration.
4. Identify common means of submitting false samples.
5. Give an example conspiracy in sample collection.

11:00-11:30 A.M. **Thinking out of the box: Do Deuterated Internal Standards Really Mimic the Drug?**
Robert W. Romberg, PhD
Senior Chemist
Navy Drug Screening Laboratory

Learning Objectives: After completing this activity, the learner will be able to:

1. Explain the use of deuterium isotopes in the laboratory.
2. Analyze different types of deuterated internal standards, elution solvents, and solid phase extraction columns to determine which is the most appropriate for an assay.

11:30-12:00 P.M. **The Science of Drinking**
Loralie Langman, PhD
Director, Toxicology and Drug Monitoring Laboratory
Mayo Clinic

Learning Objectives: After completing this activity, the learner will be able to:

1. Integrate diagnostic, clinical, and laboratory tests in the assessment of drinking.
2. Advise colleagues on the usefulness of the different tests.
3. Discuss the implications of ethical and legal issues related to cut-offs and interpretation.

12:00-1:00 P.M. **LUNCH** Ballroom CDE

1:00-2:00 P.M. **MATT Membership Meeting** Ballroom AB

2:00-2:15 P.M. **Sunshine/Wong Abstract Presentation** Ballroom AB

2:15-2:30 P.M. Break

Generic vs. Brand Name Drugs: Are They Equivalent? Ballroom AB

Moderator: Randy Schneider, PhD

2:30-3:15 P.M. **Generic vs. Brand Name Drugs: A Pharmacist's Perspective**

Garret Newkirk, PharmD
Assistant Director, Inpatient Pharmacy
Froedtert Hospital

Learning Objectives: After completing this activity, the learner will be able to:

1. Describe the process of generic drug approval.
2. Explain the role of bioequivalence in the approval of generic medications and apply the knowledge of the statistical methods for determining bioequivalence in evaluating generic vs. brand drugs.
3. Describe the role and use of generic drugs in a health-system pharmacy setting as a cost containment strategy and role in formulary management.
4. Navigate challenges in generic drug use (narrow therapeutic index drugs, transplantation drugs, epilepsy drugs).
5. Describe future challenges in the area of generic drugs: biosimilars (follow-on protein products).

3:15-4:00 P.M. **The Pharmaceutical Industry's Perspective**

Jodi Jensen, PharmD
Senior Medical Science Liaison
UCB, Inc.

Learning Objectives: After completing this activity, the learner will be able to:

1. Describe the FDA definition of generic bioequivalence
2. Demonstrate familiarity with position statements from professional and advocacy organizations on generic substitution.

4:00-4:45 P.M. **Managing the Switch: A Clinicians Experience with Anti-Epileptics**

Janel Schneider, MD
Neurologist/Epileptologist
Wheaton Franciscan Health Care

Learning Objectives: After completing this activity, the learner will be able to:

1. Describe the potential implications of changing patient medications from a "brand" to a "generic" drug.
2. Interpret therapeutic drug levels in the context of bioequivalence.
3. Assist physicians in determining which patients are better candidates for transitioning to a different formulation of the same medication.

Thursday Evening Social Event Miller Brewery

5:30-6:00 P.M. Shuttle bus to Miller Brewery Meet in Hotel Lobby

6:00-10:00 P.M. **Miller Brewery Tour**

Reception to follow in Miller Caves w/ Miller Beer and Saz's Appetizers

Friday April 30, 2010

8:00-9:00 A.M. Registration/ Hot Breakfast — Ballroom CDE

9:00-10:00 A.M. **Sponsor Presentations** — Ballroom AB

10:00-10:15 A.M. Break

Legal Issues in Toxicology

Ballroom AB

Moderator: Randy Schneider, PhD

10:15-11:00 A.M. **Interesting Forensic Toxicology Cases and Legal Loop Holes**
Ernest Chiodo, MD, JD, MPH, MS, CIH

Learning Objectives: After completing this activity, the learner will be able to:

1. Recognize the need for an integrated multi-disciplinary approach to forensic toxicological evaluation.
2. Explain the Daubert standard and other evidence rules concerning the admissibility of expert testimony in a forensic toxicology setting.
3. Discuss the importance of exposure assessment in formulations of a forensic toxicology opinion.

11:00-12:15 P.M. **Drug Impaired Driving: Don't Drive or Operate Heavy Machinery While Attending This Workshop**

1. John Gscheidmeier
   DRE Officer, City of Glendale Police Department
2. Tara Schipper
   Traffic Safety Resource Prosecutor, Department of Justice, Madison WI
3. Amy Cochems
   Advanced Chemist, Wisconsin State Laboratory of Hygiene

Learning Objectives: After completing this activity, the learner will be able to:

1. Analyze a drug impaired driver (DUID) case from three different perspectives: 1) a police officer, a laboratory toxicologist, and a prosecutor.

12:15-1:15 P.M. **LUNCH** — Ballroom CDE

Forensic Toxicology

Ballroom AB

Moderator: Paul Jannetto, PhD

1:15-2:00 P.M. **CSI Milwaukee: A Toxicologists Viewpoint**
Sue Gock, MS, MT(ASCP)
Technical Director, Forensic Toxicology
Milwaukee County Medical Examiner's Office

Learning Objectives: After completing this activity, the learner will be able to:

1. Describe the prevalence, recent trends and patterns of drug use in Milwaukee County.
2. Describe the role of the forensic toxicology lab in death investigation.
3. List the types of specimens collected and their application in postmortem toxicology testing protocols.
4. Discuss the analytical problems associated with toxicology analysis on postmortem specimens.
5. Apply forensic toxicology principles for interpretation of cause and manner of death on individual cases.

2:00-3:00 P.M. **Clinical Consequences of Forensic Toxicology**
Jerrold B Leikin MD, FACP, FACEP, FACMT, FAACT, FACOEM
Director of Medical Toxicology
NorthShore University HealthSystem-OMEGA

Learning Objectives: After completing this activity, the learner will be able to:

1. Develop the approach to evaluation of drug levels in the postmortem state.
2. Identify causes for post-mortem redistribution.
3. Discuss examples of differences between forensic and clinical drug interpretations.

3:00-3:15 P.M. Break

Poisonings in the Midwest

Ballroom AB

Moderator: Paul Jannetto, PhD

3:15-4:00 P.M. **Beer City Vignettes**
Dave Gummin, MD
Medical Director, Wisconsin Poison Control Center
Children's Hospital of Wisconsin

Learning Objectives: After completing this activity, the learner will be able to:

1. Identify the most appropriate diagnostic decisions, including laboratory analysis or bioassays in poisoning cases.
2. Recognize clinical presentation signs and symptoms and identify the most appropriate management of toxic patients.

4:00-4:45 P.M. **Pharmaceutical Diversion and Prescription Drug Abuse**
Mark Kostic, MD
Associate Medical Director, Wisconsin Poison Control Center
Children's Hospital of Wisconsin

Learning Objectives: After completing this activity, the learner will be able to:

1. Identify the latest trends in prescription diversion and drug abuse.
2. Determine the most appropriate diagnostic decisions, including laboratory analysis in prescription drug abuse cases.

4:45-5:00 P.M. **Wrap-Up and Meeting Closure** Ballroom AB

MATT WOULD LIKE TO THANK ALL OUR SPONSORS FOR SUPPORTING THIS MEETING:

GOLD Sponsors:

- UTAK Laboratories Inc.

SILVER Sponsors:

- American Institute of Toxicology Laboratories, Inc.
- Immunalysis
- Randox Laboratories, LTD
- Roche Diagnostics
- Waters Corporation

BRONZE Sponsors:

- Abbott Laboratories
- ACL Laboratories
- Agilent
- Biochemical Diagnostics
- Dynacare Laboratories
- Lake Country Pathologists
- Neogen Corporation
- Thermo Fisher Scientific
- Thermo Scientific

Finally, MATT would like to thank the

AACC TDM & Toxicology Division

for providing the ACCENT credits for this meeting.